Hemostemix Inc. (CVE:HEM – Get Free Report) traded down 8.3% during mid-day trading on Thursday . The stock traded as low as C$0.11 and last traded at C$0.11. 240,655 shares changed hands during mid-day trading, an increase of 150% from the average session volume of 96,162 shares. The stock had previously closed at C$0.12.
Hemostemix Stock Performance
The stock has a 50 day moving average of C$0.08 and a 200-day moving average of C$0.07. The company has a market cap of C$9.58 million, a PE ratio of -5.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How to Evaluate a Stock Before Buying
- 3 Legacy Tech Companies Reemerging as AI Leaders
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Financial Services Stocks Investing
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
